MA47469B1 - Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer - Google Patents

Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer

Info

Publication number
MA47469B1
MA47469B1 MA47469A MA47469A MA47469B1 MA 47469 B1 MA47469 B1 MA 47469B1 MA 47469 A MA47469 A MA 47469A MA 47469 A MA47469 A MA 47469A MA 47469 B1 MA47469 B1 MA 47469B1
Authority
MA
Morocco
Prior art keywords
treatment
imidazol
piperidin
benzo
inhibitors
Prior art date
Application number
MA47469A
Other languages
English (en)
Other versions
MA47469A (fr
Inventor
Hyung-Geun Lee
Bong-Yong Lee
Min-Jae Cho
Myung-Gi Jung
Yunju Oh
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of MA47469A publication Critical patent/MA47469A/fr
Publication of MA47469B1 publication Critical patent/MA47469B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne un composé hétérocyclique représenté par la formule chimique 1, qui peut être utilisé pour la prévention ou le traitement de maladies provoquées par une anomalie dans une activité prs (prolyl-arnt synthétase), ou un sel pharmaceutiquement acceptable de celui-ci, un procédé pour sa préparation, et une composition pharmaceutique le comprenant.
MA47469A 2017-02-07 2018-02-07 Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer MA47469B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170016971 2017-02-07
PCT/KR2018/001625 WO2018147626A1 (fr) 2017-02-07 2018-02-07 Nouveau composé hétérocyclique, son procédé de préparation et composition pharmaceutique le comprenant

Publications (2)

Publication Number Publication Date
MA47469A MA47469A (fr) 2021-06-02
MA47469B1 true MA47469B1 (fr) 2021-11-30

Family

ID=63107680

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47469A MA47469B1 (fr) 2017-02-07 2018-02-07 Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer

Country Status (31)

Country Link
US (1) US10981917B2 (fr)
EP (1) EP3580208B1 (fr)
JP (1) JP6785384B2 (fr)
KR (1) KR102084772B1 (fr)
CN (1) CN110191882B (fr)
AR (1) AR110963A1 (fr)
AU (1) AU2018218965B2 (fr)
BR (1) BR112019016291A2 (fr)
CA (1) CA3049643C (fr)
CL (1) CL2019002019A1 (fr)
CO (1) CO2019007834A2 (fr)
DO (1) DOP2019000193A (fr)
EC (1) ECSP19051409A (fr)
ES (1) ES2899665T3 (fr)
HR (1) HRP20211483T1 (fr)
HU (1) HUE056218T2 (fr)
MA (1) MA47469B1 (fr)
MX (1) MX2019009185A (fr)
MY (1) MY196538A (fr)
PE (1) PE20191477A1 (fr)
PH (1) PH12019501811A1 (fr)
PL (1) PL3580208T3 (fr)
PT (1) PT3580208T (fr)
RS (1) RS62541B1 (fr)
RU (1) RU2733384C1 (fr)
SA (1) SA519402180B1 (fr)
SG (1) SG11201906436VA (fr)
SI (1) SI3580208T1 (fr)
TN (1) TN2019000204A1 (fr)
TW (4) TWI700280B (fr)
WO (1) WO2018147626A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168082B2 (en) * 2017-05-15 2021-11-09 The Regents Of The University Of Michigan Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors
KR102346187B1 (ko) * 2019-12-26 2021-12-31 울산과학기술원 디히드로퓨란 유도체 및 이의 합성 방법
CN117320718A (zh) 2021-05-13 2023-12-29 株式会社大熊制药 用于预防或治疗纤维化的药物组合物
WO2022240035A1 (fr) 2021-05-13 2022-11-17 주식회사 대웅제약 Composition pharmaceutique destinée à la prévention ou au traitement de la fibrose
US20240307365A1 (en) 2021-07-23 2024-09-19 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical Composition for Preventing or Treating Systemic Sclerosis
WO2023055124A1 (fr) * 2021-10-01 2023-04-06 주식회사유한양행 Dérivé à noyau condensé bicyclique ou sel de celui-ci et composition pharmaceutique le comprenant
CN118401508A (zh) * 2021-12-17 2024-07-26 株式会社大熊制药 (2R,3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新酸加成盐及晶形
KR20230092630A (ko) 2021-12-17 2023-06-26 주식회사 대웅제약 (2R, 3S)-2-(벤조[d]이미다졸일프로필)피페리딘-3-올 유도체의 제조 방법
WO2023239166A1 (fr) * 2022-06-08 2023-12-14 주식회사 대웅제약 Inhibiteur d'arginase et composition pharmaceutique le comprenant
WO2024080777A1 (fr) * 2022-10-12 2024-04-18 주식회사 대웅제약 Composition pharmaceutique pour la prévention ou le traitement de la néphrite
KR20240069303A (ko) * 2022-11-11 2024-05-20 주식회사 대웅제약 방출 제어형 약학적 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8900719D0 (en) 1989-01-13 1989-03-08 Nycomed As Compounds
ES2128629T3 (es) 1994-10-31 1999-05-16 Merck Patent Gmbh Derivados de bencilpiperidina con afinidad elevada a puntos de enlace de receptores de aminoacidos.
IL114951A (en) 1995-08-15 1999-08-17 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
CA2249739A1 (fr) 1996-03-15 1997-09-25 Novartis Ag Nouvelles n-7-heterocyclyl-pyrrolo[2,3-d]pyrimidines et leur utilisation
WO2001018134A1 (fr) * 1999-08-20 2001-03-15 Csl Silicones Inc. Composition de caoutchouc d'organopolysiloxane en une seule partie utilisable en tant que revetement de protection contre la corrosion
SK10932003A3 (sk) 2001-03-15 2004-04-06 Astrazeneca Ab Metaloproteinázové inhibítory
US7307088B2 (en) * 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
US7375219B2 (en) 2005-04-13 2008-05-20 Neuraxon, Inc. Substituted indole compounds having NOS inhibitory activity
JPWO2007034882A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
CL2008000496A1 (es) 2007-02-19 2008-09-22 Smithkline Beecham Corp Compuestos derivados de purina; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades infecciosas, cancer, alergias y otras afecciones inflamatorias.
EA019204B1 (ru) * 2008-08-11 2014-01-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Производные аденина и их применение в терапии
CN102177152A (zh) * 2008-08-11 2011-09-07 哈佛大学校长及研究员协会 用于抑制tRNA合成酶的卤夫酮(halofuginone)类似物和其用途
US20130338201A1 (en) 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
US20150086627A1 (en) 2012-03-29 2015-03-26 Halo Therapeutics, Llc. Dosage forms of halofuginone and methods of use
WO2014145576A2 (fr) 2013-03-15 2014-09-18 Northwestern University Pyrrolo(2,3-d)pyrimidines substituées pour le traitement du cancer
JP6272510B2 (ja) 2014-06-23 2018-01-31 デウン ファーマシューティカル カンパニー リミテッド 新規なヘテロ環化合物
KR102277538B1 (ko) 2015-06-08 2021-07-14 주식회사 대웅제약 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물

Also Published As

Publication number Publication date
CN110191882A (zh) 2019-08-30
KR102084772B1 (ko) 2020-03-04
CN110191882B (zh) 2022-09-13
DOP2019000193A (es) 2019-08-15
TW202132279A (zh) 2021-09-01
CL2019002019A1 (es) 2019-12-13
US10981917B2 (en) 2021-04-20
TWI694070B (zh) 2020-05-21
MX2019009185A (es) 2019-09-26
TN2019000204A1 (en) 2021-01-07
BR112019016291A2 (pt) 2020-04-07
SA519402180B1 (ar) 2022-02-14
RS62541B1 (sr) 2021-12-31
EP3580208A4 (fr) 2020-08-26
KR20180091770A (ko) 2018-08-16
AR110963A1 (es) 2019-05-22
HUE056218T2 (hu) 2022-02-28
MY196538A (en) 2023-04-19
RU2733384C1 (ru) 2020-10-01
CA3049643A1 (fr) 2018-08-16
CA3049643C (fr) 2021-07-06
ES2899665T3 (es) 2022-03-14
TWI700280B (zh) 2020-08-01
TW201922723A (zh) 2019-06-16
MA47469A (fr) 2021-06-02
HRP20211483T1 (hr) 2021-12-24
AU2018218965B2 (en) 2020-06-18
CO2019007834A2 (es) 2019-07-31
AU2018218965A1 (en) 2019-07-25
TWI772759B (zh) 2022-08-01
JP2020506197A (ja) 2020-02-27
TW202030185A (zh) 2020-08-16
NZ755300A (en) 2021-10-29
PT3580208T (pt) 2021-11-18
TW201831463A (zh) 2018-09-01
SG11201906436VA (en) 2019-08-27
EP3580208A1 (fr) 2019-12-18
SI3580208T1 (sl) 2021-11-30
PH12019501811A1 (en) 2020-09-14
PE20191477A1 (es) 2019-10-16
US20190359617A1 (en) 2019-11-28
PL3580208T3 (pl) 2021-12-27
JP6785384B2 (ja) 2020-11-18
EP3580208B1 (fr) 2021-09-01
ECSP19051409A (es) 2019-07-31
WO2018147626A1 (fr) 2018-08-16
TWI782525B (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
MA47469B1 (fr) Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer
MA47368B1 (fr) N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga
MA58004B1 (fr) Dérivés de pyrazolyle utiles en tant qu'agents anticancéreux
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
ZA202200519B (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
MA47970B1 (fr) Composé inhibiteur de jak à base d'imidazo-pipéridine fusionnée
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
MA29335B1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MA42811B1 (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA49127B1 (fr) Dérivés d'indole n-substitués
MA39427A1 (fr) Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA38358A1 (fr) Formulations de composés organiques
MA39983B1 (fr) Dérivés de carboxamide
MA46268B1 (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
MA42769B1 (fr) Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
MA44965B1 (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci